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Although osteoarthritis (OA) has been traditionally regarded as a non-inflammatory dis-
ease, reports increasingly suggest that it is inflammatory, at least in certain patients. OA 
patients often exhibit inflammatory infiltration of synovial membranes by macrophages, 
T cells, mast cells, B cells, plasma cells, natural killer cells, dendritic cells, granulocytes, 
etc. Although previous reviews have summarized the knowledge of inflammation in the 
pathogenesis of OA, as far as we know, no report review our current understanding 
about T cells, especially, each T cell subtype, in the biology of OA. This review highlights 
the current understanding of the role of T cells in the pathogenesis of OA, with attention 
to Th1  cells, Th2 cells, Th9 cells, Th17  cells, Th22 cells, regulatory T  cells, follicular 
helper T cells, cytotoxic T cells, T memory cells, and even unconventional T cells (e.g., γδ 
T cells and cluster of differentiation 1 restricted T cells). The findings highlight the impor-
tance of T cells to the development and progression of OA and suggest new therapeutic 
approaches for OA patients based on the manipulation of T-cell responses.
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iNTRODUCTiON
Affecting approximately 3.8% (95% CI: 3.6–4.1) of the global population, osteoarthritis (OA) is 
regarded as a prevalent cause of morbidity and disability worldwide (1). OA shows many disease 
characteristics, such as cartilage degradation, moderate synovial inflammation, pain, alteration of 
bony structure, and impaired mobility (2). However, despite the severity of the disease, relatively little 
is known about its exact etiology. Recent compelling investigations have attributed the onset of OA 
to various person-level factors such as age, sex, obesity, and diet and joint-level factors such as injury, 
malalignment, and abnormal joint loading (3–5). Although more and more researchers have recently 
presented hypotheses concerning the involvement of these factors in OA, especially for person-level 
factors, few of their hypotheses have been demonstrated experimentally, and some have even been 
challenged by the latest observational studies and clinical trials (4, 6, 7).
Of the several factors potentially involved in the pathogenesis of OA, T cell-mediated immune 
responses and their influence on the biology of OA are the focus of this review (8–11). The scien-
tific community once understood OA to be induced by mechanical stress in the form of cartilage 
destruction, with minimal if any involvement of immune responses. Thus, OA was regarded as a 
non-inflammatory disease, in contrast with rheumatoid arthritis (RA), an inflammatory disease 
(4, 7, 12, 13). However, recent studies suggest that at least in certain patients, OA is an inflamma-
tory disease; patients have frequently been found to exhibit inflammatory infiltration of synovial 
membranes (9–11). Most recent studies have shown that the number of inflammatory cells in the 
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synovial tissue is lower in patients with OA than in patients with 
RA, but higher than that in healthy subjects (14–18). Indeed, little 
difference has been found in the percentages of T cells, B cells, 
and natural killer cells in the peripheral blood between patients 
with OA and RA (19). Leheita et al. (19) reflected on the similarity 
of the immune cell profiles of RA and OA and suggested that 
abnormalities in T cells may also contribute to the pathogenesis 
of OA. Further experiments indicated that inflammation in OA is 
anatomically restricted and varies in intensity. The synovial mem-
branes in regions rimming the cartilage of OA patients, which 
contain T cells bordered by B lymphocytes and plasma cells (20), 
showed a pronounced inflammatory response. In contrast, only 
a few infiltrating lymphocytes were observed in the synovial 
membranes taken from macroscopically non-inflamed areas 
in OA patients (20). This may explain the suggestion made by 
some researchers that immune responses are not involved in the 
pathogenesis of OA. When synovial samples from patients with 
knee OA were analyzed, the synovial lining cells showed strong 
immunoreactivity and phagocytic potential with cluster of dif-
ferentiation (CD) 68 antibodies (8). These findings suggested that 
macrophages may be associated with the pathogenesis of knee 
OA. Of 20 osteoarthritic synovial membranes, 5 showed lym-
phoid follicles containing T cells, B cells, and macrophages, and 
10 (including the latter five) displayed a diffuse cellular infiltrate 
containing T and B  cells, macrophages, and granulocytes (21). 
These results suggested that B cells and granulocytes may also be 
involved in the pathogenesis of knee OA.
To date, various immune cells have been identified in the 
synovial membranes of OA patients, such as macrophages, T cells, 
mast cells, B cells, plasma cells, natural killer cells, dendritic cells, 
and granulocytes (8, 10, 22–27). For a detailed description of the 
infiltration of synovial tissues by immune cells, a recent review 
of this subject should be consulted (10). Of these inflammatory 
cells, macrophages and T  cells most abundantly infiltrate the 
synovial tissues of OA patients. For example, macrophages rep-
resent approximately 65% of the immune cells that infiltrate the 
synovial tissues of patients with OA, and T cells make up 22% of 
the infiltrate (17). Although previous reviews have summarized 
the knowledge of inflammation in the pathogenesis of OA, as far 
as we know, no report reviews our current understanding about 
T cells, especially, each T cell subtype, in the biology of OA (9, 10, 
28). More importantly, the scientific community has recently con-
tributed to the growing literature on the involvement of T cells in 
the pathogenesis of OA with some interesting findings regarding 
the alteration of T cells during OA. Thus, this review focuses on 
our current understanding of the significance of T cells to OA 
biology.
T CeLLS AND OA
Analysis of enzyme-linked immunosorbent assay (ELISA) data 
has shown that compared with age-matched healthy controls, 
patients with OA show higher levels of the soluble form of CD4 
(sCD4) in their serum. This suggests that peripheral T helper (Th) 
cells are involved in the pathogenesis of OA (29). Similarly, when 
stimulated with phorbol myristate acetate (PMA) and ionomycin, 
peripheral mononuclear cells from OA patients showed a higher 
expression of CD4 and CD8 markers than their counterparts 
from healthy controls (30). Indeed, the ratio of CD4+/CD8+ 
in the blood of OA patients is higher than that in the blood of 
healthy controls, although healthy controls and OA patients have 
fairly similar numbers of CD4+ and CD8+ T cells in their blood 
(31). Further evidence of the involvement of peripheral T cells 
in the pathogenesis of OA was provided by the discovery that 
the response to autologous chondrocytes of peripheral T  cells 
isolated from OA patients is greater than of peripheral T  cells 
isolated from controls and that this response is partially blocked 
by antibodies against human leukocyte antigen (HLA) classes I 
and II, CD4, and CD8 (32). Interestingly, T cells in a subset of OA 
patients were found to recognize the peptides representing amino 
acid regions 16–39 and 263–282 of human cartilage proteoglycan 
aggrecan (PG), and peripheral blood mononuclear cells from 
these PG-reactive OA patients showed an increased production 
of pro-inflammatory cytokines/chemokines in response to PG 
peptide stimulation (33). Based on these compelling findings, the 
autoimmune responses of peripheral T cells may aid understand-
ing of immune-mediated mechanisms in OA.
Enzyme-linked immunosorbent assay analysis revealed higher 
levels of sCD4 not only in the peripheral blood but also in the 
synovial fluid of patients with OA, compared with age-matched 
healthy controls, which suggests that Th cells in the synovial fluid 
are involved in the pathogenesis of OA (29). When stimulated 
with PMA and ionomycin, mononuclear cells from the synovial 
fluid of OA patients showed a high expression of CD4 and CD8 
markers (30). These compelling results suggested that T cells in 
the synovial fluid are associated with the pathogenesis of OA. 
This conclusion was supported by subsequent investigations. For 
example, the percentage of T  cells in the synovial fluid of OA 
patients was found to be significantly higher than that in their 
peripheral blood (34), and T  cells in the synovial fluid of OA 
patients expressed class II HLA (an indicator of activated T cells) 
(35). The percentages of CD4+ and CD8+ cells in the synovial fluid 
of OA patients were even similar to those found in RA patients 
(31).
T cells are the major constituents of synovial infiltrates in the 
membranes of OA patients, and both CD4+ T cells and CD8+ T cells 
have been found within synovial aggregates (35). For example, 
synovial tissue extracted from OA patients displayed perivascular 
CD3+ T  cell infiltration at an early stage (36). Similarly, using 
immunohistochemical analysis, CD3+, CD4+, and CD8+ T cells 
were detected predominantly in the sublining layer and more 
limitedly in the deep layer of the synovium of patients with OA, 
whereas the presence of CD4+ T cells in the synovial sublining 
layer was detected more strongly in OA patients than in normal 
subjects (15). CD4+ T cells were found to be predominant among 
the T-cell infiltrates in the synovial tissue, and the number of 
CD4+ T cells was higher in the synovial sublining layer of patients 
with OA than in that of normal subjects. Indeed, the medial 
synovium of patients with knee OA has been shown to contain 
more CD4+ T cells than the lateral synovium (8). Interestingly, 
synovial aggregates from OA patients express CD80, an induc-
ible costimulatory ligand involved in T-cell activation (35, 37), 
suggesting that synovial aggregates in OA patients are areas of 
antigen recognition and T-cell activation. Similarly, researchers 
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investigating 30 patients with OA found CD3+ T cell aggregates in 
the synovial membrane in 65% of the patients, and the activation 
antigens CD69, CD25, CD38, CD43, CD45RO, and HLA class 
II were also found in the synovial membrane (38). In addition, 
HLA-antigen D-related (DR)-expressing T cells were found in the 
synovial membranes of OA patients using immunohistochemical 
analysis, although to a lesser degree than in RA patients (39). The 
conclusion that activated T cells are aggregated in the synovial 
membranes of OA patients was further supported by the discovery 
that virtually all T cells in OA joints express activation markers, 
such as HLA-DR and CD69 (40). Interestingly, OA patients older 
than 75 have higher percentages of CD3+, CD4+, and CD8+ cells 
in their synovial membranes than OA patients younger than 75 
(41). This may suggest that age is among the risk factors for OA.
Collectively, significant abnormalities in the T-cell profile have 
been found in the peripheral blood, synovial fluid, and synovial 
membranes of OA patients. Based on these findings, T cells are 
assumed to be associated with the pathogenesis of OA.
Th1 and OA
Under the stimulation of interleukin (IL)-12, naïve CD4+ T cells 
differentiate into Th1  cells, which produce IL-2, interferon 
(IFN)-γ, tumor necrosis factor (TNF)-α, lymphotoxins, and 
granulocyte-macrophage colony-stimulating factor (42–44). 
Most current evidence indicates that Th1 cells do not alter sig-
nificantly on entering the peripheral blood of OA patients. For 
example, flow cytometry analysis has shown that there is little 
difference in the percentage of circulating Th1 cells (CD4+IFN-γ+ 
T cells) between OA patients and healthy controls (45). Similarly, 
no variation in either the percentage or the absolute number 
of circulating Th1  cells (CD4+IFN-γ+ T  cells) has been found 
between patients with OA and healthy controls (46). However, in 
a study with 25 OA patients and 13 healthy controls, the number 
of circulating Th1 cells (IFN-γ+CD4+CD8− T cells) and the level 
of serum IFN-γ were found to be significantly higher in patients 
with OA than in healthy controls (47). The difference in the mark-
ers (CD4+IFN-γ+ vs. IFN-γ+CD4+CD8−) used in the two studies 
to define Th1  cells may account for this discrepancy. Another 
explanation may lie in the variation between OA patients, such 
as differences between the stages of OA. The alteration of the 
Th1  cell profile in the peripheral blood of OA patients thus 
requires further investigation.
In contrast with the findings for peripheral blood, the synovial 
fluid of OA patients shows an increase in Th1  cells. Although 
early experiments suggested that the concentrations of IL-2, IFN-
γ, and TNF-β in the synovial fluid of OA patients are below the 
limit of detection by ELISA analysis (48), reverse transcription 
polymerase chain reaction (RT-PCR) analysis has since revealed 
that cells from the synovial fluid of OA patients express IL-2 and 
IFN-γ when stimulated with PHA and ionomycin (35). Indeed, 
intracellular IFN-γ has been detected at higher levels in both 
CD4+ and CD8+ cells from the synovial fluid than in the periph-
eral blood of OA patients (30). In addition, high concentrations 
of IL-1β and TNF-α have been observed in the synovial fluid of 
patients with OA, whereas these markers are below the limit of 
detection in healthy subjects (31).
Th1 cells can also be found in the synovial membranes of OA 
patients. For example, IL-2, IFN-γ, and their receptors are usu-
ally detected in the synovial membranes of OA patients (38, 49). 
Similarly, INF-γ+ cells have been detected in the synovial mem-
branes of patients with OA, predominantly in the sublining layer 
of the synovium, although to a lesser degree than in RA patients 
(15). In a mouse model of OA induced by anterior cruciate 
ligament transection (ACLT), the expression of IFN-γ increased 
during OA onset (30 days after ACLT) and then decreased at a 
later stage of OA (90 days after ACLT) (50). Most importantly, 
a well-designed study showed that Th1 cells are predominant in 
both OA and RA joints (40). Indeed, the number of IFN-γ+ cells 
in the synovium of patients with OA is approximately five times 
greater than that of IL-4+ cells (15).
In summary, although the profile of Th1 cells in the periph-
eral blood requires further analysis, Th1 cells have been shown 
to accumulate in the synovial fluid and synovial membranes of 
OA patients, which suggests that Th1 cells play important roles 
in the pathogenesis of OA. In addition, Th1 cell responses in the 
synovial fluid and synovial membranes of OA patients may be a 
marker of OA disease activity.
Th2 and OA
When stimulated by IL-4, naïve CD4+ T cells differentiate into 
Th2 cells (44). Through the production of IL-4, IL-5, IL-10, and 
IL-13, Th2 cells affect the function of B  cells, dendritic cells, 
eosinophils, etc. and play important roles in the host’s defense 
against multicellular parasites and in the pathogenesis of aller-
gies (42, 43, 51–54). Most recent studies have shown that Th2 
cells undergo limited alteration in the peripheral blood, synovial 
fluid, and synovial membranes of OA patients. For example, in a 
study of 18 OA patients, the IL-10 transcript was found in nearly 
all of the patients using competitive PCR analysis, whereas IL-4 
and IL-5 were not detected in the synovial membranes of any of 
the patients (38). Similarly, the concentrations of IL-4 and IL-10 
in the synovial fluid were below the limit of detection by ELISA 
analysis (48). Using flow cytometry analysis, low concentrations 
of Th2 cytokines such as IL-4 and IL-10 were detected in both 
the synovial fluid and the peripheral blood of OA patients (30). 
Although cells from the synovial fluid of OA patients stimulated 
with PHA and ionomycin expressed IL-10 at 48 h poststimula-
tion, no signal for IL-4 was detected by RT-PCR analysis (35). The 
observed expression of IL-10 in OA patients’ synovial membranes 
or synovial fluid cells may come from other cells, such as regula-
tory T cells (Treg cells).
Together, although these compelling findings suggest that 
Th2 responses play only a limited role in the pathogenesis of OA, 
further strong evidence is needed to support this hypothesis.
Th9 and OA
Th9 cells, recently defined as subsets of Th cells, preferentially 
produce IL-9 (44, 55–57). Th9 cells facilitate immune responses 
against melanoma and intestinal worms and are closely 
associated with the immunopathology of allergic and autoim-
mune responses, such as systemic lupus erythematosus (SLE), 
experimental autoimmune encephalitis, and systemic sclerosis 
(55–57).
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Th9 cells are also involved in the pathogenesis of arthritis. For 
example, a high level of IL-9 has been detected in the peripheral 
blood and synovial fluid of patients with RA and patients with 
psoriatic arthritis (PsA), and the level of IL-9 in the synovial 
fluid is higher than that in the peripheral blood for RA and PsA 
patients (58). Similarly, activated CD3+ T cells from the peripheral 
blood and synovial fluid of patients with PsA or RA produce high 
levels of IL-9 (58). These results suggest that Th9 cells play critical 
roles in the pathogenesis of RA and PsA. Indeed, Th9 responses 
have also been observed in OA. For example, a high level of IL-9 
has been detected in the peripheral blood and synovial fluid of 
OA patients, and the activation of purified CD3+ cells from the 
peripheral blood and synovial fluid of patients with OA produces 
a high level of IL-9, although lower than that observed in RA or 
PsA patients (58). Even more importantly, in a study with 25 OA 
patients and 13 healthy controls, the number of circulating Th9 
cells and serum IL-9 level were found to be significantly higher in 
OA patients than in healthy controls (47). This study also found 
that the number of circulating Th9 cells was positively associ-
ated with the level of C-reactive protein in OA patients and that 
both the number of Th9 cells and the level of serum IL-9 were 
positively correlated with OA index (47).
In summary, these well-designed experiments lead to the con-
clusion that Th9 cells significantly shape the pathogenesis of OA, 
as well as that of RA and PsA; however, the Th9 response in the 
synovial membranes of OA patients needs further investigation. 
In addition, serum IL-9 or the number of circulating Th9 cells 
may be a marker of OA disease activity.
Th17 and OA
Th17 cells secrete IL-17A (also known as IL-17), IL-17F, IL-21, and 
IL-22. Transform growth factor (TGF)-β, IL-6, IL-1β, and IL-23 
have been reported to promote the differentiation of Th17 cells 
(44, 59–63). Th17 cells provide protection against bacterial infec-
tion and are associated with the development of autoimmune 
diseases via the recruitment of cells in the granulocyte lineage, 
especially neutrophils (64–67). Early investigations indicated 
that neither the percentages of circulating pure Th17 cells (CD4+ 
IFN-γ−IL-22−IL-17+ T cells) and Th17 cells (CD4+IL-17+ T cells) 
nor the level of serum IL-17 differed significantly between OA 
patients and healthy controls (45). Similarly, no variation in the 
percentage or absolute number of circulating Th17 cells or the 
IL-17 plasma level was found between patients with OA and 
healthy controls (46). These findings indicated that little altera-
tion occurs in the Th17 cell profile in the peripheral blood of OA 
patients. However, later observations suggested otherwise. In a 
rat model of OA induced by the injection of papain and l-cysteine 
into the right knee joint, the OA rats were found to have a higher 
serum IL-17 level than the control rats (68). In addition, in a 
study with 25 OA patients and 13 healthy controls, the number 
of circulating Th17 cells and the level of serum IL-17 were found 
to be significantly higher in patients with OA than in healthy 
controls (47). As in the case of Th1 cells, variation in the markers 
used to define Th17 cells (CD4+IL-17+ vs. IL-17+CD4+CD8−) and 
the patients selected for investigation (e.g., diagnosis standard, 
disease index, patients’ background) may account for this dis-
crepancy. These controversial findings regarding Th17 cell profile 
in the peripheral blood of OA patients suggest that the roles of 
circulating Th17  cells in the pathogenesis of OA need further 
investigation. Nevertheless, it is widely accepted that Th17 cells 
are present in the synovial fluid and synovial membranes of OA 
patients. For example, in addition to the strong expression of 
IL-17 mRNA in the synovial membranes of OA patients (69), a 
high level of IL-17 has been measured in the synovial fluid of OA 
patients, whereas both are below the limit of detection in healthy 
subjects (31, 70). In addition, Th17 cells have been detected in 
the joints of OA patients, albeit in smaller numbers than in RA 
joints (40).
Collectively, these interesting results demonstrate the accu-
mulation of Th17 cells in the synovial fluid and synovial tissue of 
OA patients; however, the exact role of Th17 cell response in the 
biology of OA needs further investigation.
Th22 and OA
Originally, IL-22 was regarded as a product of Th17  cells; 
however, recent evidence has indicated that a distinct subset of 
human skin CD4+ T cells (Th22) produces IL-22 but not IL-17 
or IFN-γ (71). Increasing evidence has been provided for the 
involvement of Th22 cells in the biology of RA. For example, 
the percentage of Th22 cells is higher in RA patients than in 
healthy controls, and the percentage of Th22 cells is positively 
correlated with IL-22 expression in RA patients (45). In addi-
tion, the percentage of Th22 cells is positively correlated with 
both C-reactive protein levels and joint disease activity scores 
in RA patients (45). These compelling discoveries indicate that 
Th22 response is associated with the pathogenesis of RA and 
that blocking IL-22 expression may be a reasonable therapeutic 
strategy for RA. Th22 cells are also involved in the biology of 
ankylosing spondylitis. Similar to the results for RA, the percent-
age and absolute number of circulating Th22 cells were found 
to be elevated in patients with ankylosing spondylitis compared 
with healthy controls (46). Similarly, ELISA analysis revealed 
that the level of IL-22 in the plasma was higher in patients with 
ankylosing spondylitis than in healthy controls (46). However, 
Th22 cells seem to play a limited role in the pathogenesis of OA. 
For example, compared with healthy controls, OA patients show 
no change in the percentage of circulating Th22 cells (CD4+ 
IFN-γ−IL-17−IL-22+ T cells) and the level of IL-22 in the plasma 
(45). Similarly, another independent experiment revealed that 
neither the percentage nor the absolute number of circulating 
Th22 cells, nor the plasma level of IL-22, differ between patients 
with OA and healthy controls (46).
Collectively, unlike RA and ankylosing spondylitis, OA involves 
only a limited alteration of Th22 response in the peripheral blood; 
however, we lack data on the Th22 profile in the synovial fluid and 
synovial tissue of OA patients.
Treg Cells and OA
Under the influence of TGF-β, naïve T  cells differentiate into 
Treg cells, which produce IL-10 and TGF-β (43, 72–74). Treg 
cells are important immunoregulators in many inflammatory 
and autoimmune diseases, as they modulate the secretion of 
anti-inflammatory cytokines and the expression of receptors 
for cytokines (75). For example, RA patients have a lower 
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percentage of Treg cells at sites of synovial inflammation and in 
the peripheral blood (76), which may induce the downregula-
tion of T-cell tolerance and exacerbate the inflammatory pro-
cess. Increasing evidence has been provided that the profile of 
Treg cells in the peripheral blood, synovial fluid, and synovial 
membranes of OA patients is similar to that of RA patients. For 
example, the percentage and absolute number of Treg cells (CD4+ 
CD25+/highCD127−/low) in the peripheral blood, synovial fluid, and 
synovial membranes are similar in RA patients and OA patients, 
and Treg cells in both cases show greater accumulation in the syn-
ovial fluid and synovial membranes than in the peripheral blood 
(77). In addition, Treg cells in the peripheral blood, synovial fluid, 
and synovial membranes of both OA patients and RA patients 
display a memory phenotype (CD45RO+RA−) (77). Neither does 
the activation status (CD69 and CD62L) nor the expression of 
markers associated with Treg function (CD152, CD154, CD274, 
CD279, and GITR) in the peripheral blood, synovial fluid, or 
synovial membranes differ between OA patients and RA patients 
(77). Those compelling results indicate that as in the case of RA, a 
decrease in Treg-cell responses is involved in the pathogenesis of 
OA. Indeed, Ponchel et al. (11) analyzed blood from 121 healthy 
controls and 114 OA patients and found that the OA patients had 
fewer Treg cells than the healthy controls after adjusting for age 
(11). Although the frequency of CD4+CD25+Foxp3+ Treg cells 
has been found to be elevated in the blood of OA patients, OA 
patients show lower IL-10 secretion from Treg cells and fewer 
Tim-3+ Treg cells in the blood (78). Similarly, in a rat model of OA 
induced by the injection of papain and l-cysteine into the right 
knee joint, the percentage of CD4+CD25+Foxp3+ Treg cells in the 
peripheral blood was significantly lower in the OA rats than in 
the control rats (68).
In summary, a decrease in Treg-cell response may be involved 
in the pathogenesis of OA; however, the alteration of Treg-cell 
responses in the peripheral blood, synovial fluid, and synovial 
membranes of OA patients requires more comparative investiga-
tion with age-matched healthy controls.
Follicular Helper T (Tfh) Cells and OA
Follicular helper T cells, located in the follicles of lymphoid tissue, 
induce B cells to produce immunoglobulins (79). Tfh cells express 
various distinguishing genes, such as CXCR5, PD-1, ICOS, CD40L, 
Bcl-6, and IL-21 (80). Increasing evidence has been provided for 
the influence of Tfh cells on the severity of autoimmune diseases, 
such as SLE and RA. For example, the number of circulating Tfh 
cells (CXCR5+ICOS+CD4+ cells or CXCR5+PD-1+CD4+ cells) has 
been shown to increase in a subset of SLE patients in line with the 
diversity and concentration of autoantibodies and SLE severity 
(81). Similarly, immunohistochemistry analysis has revealed spe-
cific staining for CD4, CXCR5, and ICOS on infiltrating immune 
cells in the synovial tissues of RA patients, and the presence of Tfh 
cells (CD4+CXCR5+ICOS+ T cells) in the synovial tissues of RA 
patients has been verified using both triple-fluorescence immu-
nostaining and confocal laser scanning (82). This study provided 
evidence of the presence of Tfh cells in both SLE and RA patients, 
indicating the potentially important roles played by Tfh cells in 
the pathogenesis and progression of both diseases. However, the 
results of immunohistochemistry analysis, triple-fluorescence 
immunostaining, and confocal laser scanning revealed that Tfh 
cells are absent from the synovial tissues of OA patients (82). Yet, 
a recent investigation demonstrated the importance of Tfh cells 
to the pathogenesis and progression of OA. In the latter study, 
the frequency of ICOS+, PD-1+, and IL-21+ CXCR5+CD4+ T cells 
in the peripheral blood of 40 patients with OA and 13 healthy 
controls was examined by flow cytometry, and the concentra-
tion of serum IL–21 was also determined. Compared with the 
healthy controls, the OA patients showed higher percentages of 
CXCR5+CD4+, PD-1+CXCR5+CD4+, ICOS+CXCR5+CD4+, and 
IL-21+CXCR5+CD4+ T cells (83). Shan et al. (83) also found that 
OA patients exhibited higher levels of serum IL-21 than healthy 
controls and, even more importantly, that the expression of 
IL-21+Tfh cells in OA patients was positively correlated with the 
disease activity of OA (83). The latter study suggests that Tfh cells 
play a critical role in the pathogenesis and progression of OA. 
However, further well-designed research is needed to character-
ize Tfh cell profile in the peripheral blood, synovial fluid, and 
synovial membranes of OA patients.
Cytotoxic T Cells and OA
The peripheral blood of OA patients has been analyzed using 
flow cytometry, revealing that patients with OA have significantly 
fewer CD8+ T cells and a higher CD4+:CD8+ ratio than healthy 
subjects (84). However, patients with OA have normal propor-
tions of CD8+CD45RA+, CD8+CD29+, and CD8+S6F1+ cells in 
both their peripheral blood and their synovial fluid (85). These 
results indicate the alteration of peripheral CD8+ T cells in OA 
patients. Although CD8+ T  cells can be found in the synovial 
membranes of OA patients, the major component of the T-cell 
infiltrate cannot. Most of the T cells found in the synovial mem-
branes of patients with OA are helper T cells, whereas cytotoxic 
T  cells occur sparsely in patients with OA (39, 86). Similarly, 
fewer CD8+ T  cells than CD4+ T  cells have been found in the 
lining, the sublining, and even the deep layer of the synovium 
of patients with OA (15). In addition, although both CD4+ and 
CD8+ T cells have been found in the synovial aggregates of OA 
patients, the aggregates contain a larger proportion of CD4+ 
T cells than of CD8+ T cells, and the CD8+ T cells are often located 
toward the periphery of the aggregates (35). CD8+ T cells play 
an important role in the pathogenesis of OA, although they are 
not the predominant T-cell type found in the synovial aggregates 
of OA patients. In mice with ACLT-induced OA, CD8+ T cells 
were activated once OA had been initiated, and the percentage 
of activated CD8+ T cells was significantly higher in the ACLT 
group than in the sham group during OA progression (87). In 
addition, the number of CD8+ T cells expressing tissue inhibi-
tor of metalloproteinase-1 (TIMP-1) was found to be correlated 
with OA severity and inhibiting the expression of TIMP-1 in the 
joints retarded the progression of OA (87). Cartilage degenera-
tion occurred more slowly in CD8+ T cell knockout mice than in 
wild-type mice (87).
In summary, a significant alteration to CD8+ T  cells has 
been observed in the peripheral blood, the synovial fluid, and 
the synovial membranes, and CD8+ T cells have been found to 
significantly shape the pathogenesis of OA, although they do not 
play the most important role in the process.
FigURe 1 | The involvement of T cells in the pathogenesis of osteoarthritis (OA). T cells, including the T helper (Th) cells, cytotoxic T cells, and T memory 
(Tm) cells, have critical importance in the pathogenesis of OA (++). The involvement of unconventional T cells in the pathogenesis of OA is not shown here. Within T 
helper (Th) cells, Th1 cells, Th9 cells, Th17 cells, and follicular helper T (Tfh) cells increase in the peripheral blood, synovial fluid, or synovial membranes of OA 
patients (++). The numbers of cytotoxic T cells and Tm cells also increase in the OA. However, the numbers of Th2 cells and Th22 cells show limited alteration in the 
pathogenesis of OA (−), but the number of Treg cells decrease during the OA (−−).
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T Memory (Tm) Cells and OA
Once activated, most T  cells undergo apoptosis; however, a 
minority persist as Tm cells. An increasing number of researchers 
have begun to investigate the profile of Tm cells in the patho-
genesis of OA. For example, although healthy individuals showed 
no difference in the percentages of CD45RO+CD4+ T cells and 
CD45RA+CD4+ T cells in the peripheral blood, more CD45RO+ 
cells than CD45RA+ cells were found in the peripheral blood of 
patients with OA (88). In patients with OA, the majority of CD4+ 
T  cells in the synovial fluid and synovial tissue are CD45RO+ 
and CD45RA−, suggesting that an accumulation of CD45RO+ 
memory CD4+ T cells is a generalized phenomenon in OA joints 
(88). Similarly, a study with 25 OA patients and 13 healthy controls 
revealed that the number of circulating CD4+CD45RO+ T cells 
was significantly higher in patients with OA than in healthy con-
trols (47). Other evidence for the possible involvement of Tm cells 
in the pathogenesis of OA includes the detection of the regulated 
on activation, normal T cell expressed, and secreted chemokine 
(a potent chemoattractant for leukocytes, such as CD45RO+ 
memory T cells) and CD29 (a 1 integrin expressed by Tm cells) 
in the synovial fluid of OA patients (35, 37, 89).
In summary, CD45RO+ memory CD4+ T cells seem to be criti-
cal to the biology of OA, yet their exact roles in the pathogenesis 
of OA have yet to be determined.
Unconventional T Cells and OA
Recent investigations have also highlighted the involvement of 
unconventional T cells in the pathogenesis of OA. For example, 
more and more evidence has been provided that γδ T cells are 
involved in the pathogenesis of RA. For example, the number of 
γδ T cells has been found to increase in the synovial membranes 
of RA patients (90–93), and γδ T cells in the synovial membranes 
have more and/or more avid Fc receptors for immunoglobulin 
G IgG in patients with RA compared with controls (90). Further 
research has shown that the majority of synovial γδ T cells in RA 
patients do not express Vγ9, Vδ2, or Vδ1-Jγδ1 (91). However, 
most recent studies have indicated that the number of γδ T cells 
in the synovial membranes of patients with OA does not increase 
(91–93). Immunohistochemical staining of synovial tissue with 
early-stage OA shows T-cell infiltration in the perivascular area, 
with the clonality of restricted T  cell receptor usage in the V 
beta chain (36), which also indicates the minimal alteration of 
γδ T  cells in OA patients. Recent studies have shown that the 
synovial membranes of OA patients express CD1 (94), which 
presents non-protein antigens to NKT  cells, suggesting that 
CD1-restricted T cells may play a role in the pathogenesis of OA.
Overall, although numerous studies of the involvement 
of conventional T  cells in OA have been conducted, it will be 
useful to determine the importance to OA of unconventional 
T cells such as CD1-restricted T cells, MR1-restricted mucosal-
associated invariant T  cells, major histocompatibility complex 
class Ib-reactive T cells, and γδ T cells (95).
CONCLUSiON
Various risk factors for OA have been proposed, ranging from 
person-level factors such as age, sex, and obesity, to joint-level 
factors such as injury, malalignment, and abnormal loading of 
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joints (3–5). Increasing evidence has also been provided that 
inflammation is associated with the development and progression 
of OA, at least in certain patients. OA patients often exhibit the 
infiltration of synovial membranes by inflammatory cells such as 
macrophages, T cells, mast cells, B cells, plasma cells, natural killer 
cells, dendritic cells, and granulocytes (8–11). Several scholars 
have investigated the alteration of T cells during the pathogenesis 
of OA, with reference to Th1 cells, Th2 cells, Th9 cells, Th17 cells, 
Th22 cells, Treg cells, Tfh cells, cytotoxic T cells, Tm cells, and 
even unconventional T cells (e.g., γδ T cells and CD1-restricted 
T  cells). To date, it has been widely accepted that a significant 
alteration occurs in the profiles of Th1 cells, Th9 cells, Th17 cells, 
Treg cells, cytotoxic T cells, and Tm cells in the peripheral blood, 
synovial fluid, and synovial membranes of OA patients (Figure 1; 
Table 1). However, the involvement of Th2 cells, Th22 cells, Tfh 




Alterations in the OA Reference
Th1 cells IL-2, IFN-γ, 
TNF-α
Peripheral blood No (45, 46)
Synovial fluid Increase (30, 31, 35)
Synovial membrane Increase (15, 38, 40, 
49, 50)
Th2 cells IL-4, IL-5, IL-10, 
IL-13
Peripheral blood No (30)
Synovial fluid No (30, 35, 48)
Synovial membrane No (38)
Th9 cells IL-9 Peripheral blood Increase (47, 58)
Synovial fluid Increase (58)
Synovial membrane –
Th17 cells IL-17A, IL-17F, 
IL-21, IL-22
Peripheral blood No (45, 46)
Increase (47, 68)
Synovial fluid Increase (31, 70)
Synovial membrane Increase (40, 69)
Th22 cells IL-22 Peripheral blood No (45, 46)
Synovial fluid –
Synovial membrane –








Peripheral blood Increase (83)
Synovial fluid –
Synovial membrane No (82)
Cytotoxic 
T cells
Peripheral blood Decrease (84)
Noa (85)
Synovial fluid Noa (85)
Synovial membrane Increase (15, 35, 39, 
86)
IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; TGF, transform growth factor; 
CXCR5, C-X-C chemokine receptor type 5; PD-1, programmed death 1; –, further 
investigations are needed; OA, osteoarthritis; Th, T helper; Treg, regulatory T.
aCD8+CD45RA+, CD8+CD29+, and CD8+S6F1+ cells.
cells, and unconventional T cells in the pathogenesis of OA needs 
further investigation (Figure 1; Table 1). In addition, the causal 
relationship between the alteration of T-cell responses and the 
development and progression of OA has yet to be identified. 
Various factors such as extracellular stimulation (e.g., antigens), 
intracellular signaling [e.g., mTOR complex 1 (mTORC1)], and 
cell metabolism (e.g., amino acid metabolism) are significant 
determinants of the fate of T cells (54, 66, 96–100). Therefore, it 
will be interesting to manipulate these factors to determine their 
precise effects on the development and progression of OA. For 
example, mTORC1 is known to regulate Th17 differentiation and 
IL-17 expression through several pathways, including STAT3, 
HIF-1α, S6K1, and S6K2, which raises the possibility of regulating 
the pathogenesis of OA through mTORC1 signaling (66). Indeed, 
the great importance of mTORC1 signaling to the pathogenesis 
of OA has recently been highlighted (101). The metabolism and 
transportation of amino acids also have a remarkable influence 
on T-cell activation and differentiation, especially for Th1 and 
Th17  cells, suggesting that amino acid metabolism also affects 
the pathogenesis of OA. Indeed, the establishment and develop-
ment of OA are associated with alterations in the metabolism 
and profile of amino acids such as those of the glutamate and 
arginine families, as well as their related metabolites (e.g., cre-
atinine, hydroxyproline, γ-aminobutyrate, dimethylarginines, 
and homoarginine) (4). Furthermore, intestinal microbiota have 
vital roles in T-cell responses, especially those of Th17 cells (102, 
103), indicating the critical functions of intestinal microbiota in 
the pathogenesis of OA. Indeed, intestinal microbiota have been 
proposed as a risk factor in the development and progression of 
OA (7, 104). Understanding the significance of the altered T-cell 
profile to the pathogenesis of OA will open up novel directions 
for preventing and treating OA by modulating T-cell responses.
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